Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 11/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198914 | 0.76 | P2RX4 (0.37) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL29434173 | 0.76 | P2RX4 (0.37) | MAPK1LMNATSHRSCN4ASCN5A | |
| Iodide SCHEMBL7101346 | 0.74 | P2RX4 (0.36) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL374978 | 0.74 | MAPK1 (0.39) | MAPK1LMNATSHRSCN4ASCN5A | |
| Iodide SCHEMBL30253496 | 0.74 | P2RX4 (0.36) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL2073989 | 0.74 | MAPK1 (0.35) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL4838385 | 0.74 | LMNA (0.39) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL8857358 | 0.74 | MAPK1 (0.35) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL5213962 | 0.74 | MAPK1 (0.35) | MAPK1LMNATSHRSCN4ASCN5A | |
| Hydrochloric Acid SCHEMBL29035745 | 0.74 | MEN1 (0.37) | MAPK1LMNATSHRSCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| CN-109121397-A | Heterocyclic compound, especially 2- oxo -4,4,5,5,6,6,7,7- octahydro benzoxazoles derivatives and their purposes as antimicrobial compound | 莱德克斯制药公共有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2018-02-01 | — | — | US | disclosed |
| US-9809561-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160304476-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| WO-2015095795-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| CN-101240001-B | 2' -fluoro nucleosides | UNIV EMORY | 2013-10-16 | — | — | CN | disclosed |
| EP-2638014-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR ACTIVITY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| CN-101089010-B | 2' -fluoronucleosides | EMORY UNIVERSITY (US) | 2011-12-14 | — | — | CN | disclosed |
| CN-101240001-A | 2' -fluoro nucleosides | UNIV EMORY (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-101089010-A | 2' -fluoronucleosides | UNIV EMORY (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-100349913-C | 2' -fluoro nucleosides | UNIV EMORY (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1332747-A | 2' -fluoro nucleosides | UNIV EMORY (US) | 2002-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | MAPK1 4228/4885LMNA 3604/4885TSHR 172/4885 |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | MAPK1 4228/4885LMNA 3604/4885TSHR 172/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | MAPK1 4228/4885LMNA 3604/4885TSHR 172/4885 |
| US-20160304476-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | MAPK1 4228/4885LMNA 3604/4885TSHR 172/4885 |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | MAPK1 3450/4885LMNA 4006/4885TSHR 1925/4885 |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | MAPK1 4230/4885LMNA 3553/4885TSHR 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.